Ensuring uninterrupted supplies of antiretroviral drugs in resource-poor settings: an example from Malawi

被引:35
作者
Harries, Anthony D.
Schouten, Erik J.
Makombe, Simon D.
Libamba, Edwin
Neufville, Henry N.
Some, Eliab
Kadewere, Godfrey
Lungu, Douglas
机构
[1] Minist Hlth, Clin HIV Unit, Lilongwe, Malawi
[2] UNICEF, Malawi Country Off, Lilongwe, Malawi
[3] Minist Hlth, Dept Hlth Tech Serv, Lilongwe, Malawi
[4] Minist Hlth, Dept Clin Serv, Lilongwe, Malawi
关键词
D O I
10.2471/BLT.06.032060
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Problem Drug procurement and distribution practices are weak in many resource-poor countries, and are a major reason for lack of access to medicines. With many countries scaling up antiretroviral therapy (ART), it is vital to avoid interrupted drug supplies, which would lead to drug resistance and treatment failure. Approach Malawi has adapted a model, based on that adopted by the country's Tuberculosis Control Programme, to allow rational ART drug forecasting. Local setting The model includes a focus on one standardized first-line ART regimen; a "push system" and "ceilings" for first-line ART drugs for facilities; use of starter pack and continuation pack kits; quarterly monitoring of patient outcomes and ART drug stocks at facility level; provision of a three-month buffer stock of ART drugs at facility level; and use of a procurement and distribution system outside central medical stores. Lessons learned The focus on a single first-line regimen, "ceilings" for first-line ART drugs and quarterly data collections to calculate drug needs (for new and follow-up patients, respectively), as well as the use of an independent procurement facility, allow drug orders to be made 6-9 months ahead. These measures have so far ensured that there have been no ART drug stock-outs in the country.
引用
收藏
页码:152 / 155
页数:4
相关论文
共 10 条
[1]  
Quick J.D., Boohene N.-A., Rankin J., Mbwasi R.J., Medicines supply in Africa, BMJ, 331, pp. 709-710, (2005)
[2]  
Progress on global access to HIV antiretroviral therapy. An update on "3 by 5". June 2005, (2005)
[3]  
Weiser S., Wolfe W., Bangsberg D., Thior I., Gilbert P., Makhema J., Et al., Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana, J Acquir Immune Defic Syndr, 34, pp. 281-288, (2003)
[4]  
Elise A., France A.M., Louise W.M., Bata D., Francois R., Roger S., Et al., Assessment of adherence to highly active antiretroviral therapy in a cohort of African HIV-infected children in Abidjan, Cote d'Ivoire, J Acquir Immune Defic Syndr, 40, pp. 498-500, (2005)
[5]  
Spacek L.A., Shihab H.M., Kamya M.R., Mwesigire D., Ronald A., Mayanja H., Et al., Response to antiretroviral therapy in HIV-infected patients attending a public urban clinic in Kampala, Uganda, Clin Infect Dis, 42, pp. 252-259, (2006)
[6]  
Treatment of tuberculosis: Guidelines for national programmes, (2003)
[7]  
Scaling up antiretroviral therapy in resourcelimited settings: Treatment guidelines for a public health approach. 2003 revision, (2003)
[8]  
Harries A.D., Libamba E., Schouten E.J., Mwansambo A., Salaniponi F.M., Mpazanje R., Expanding antiretroviral therapy in Malawi: Drawing on the country's experience with tuberculosis, BMJ, 329, pp. 1163-1166, (2004)
[9]  
Libamba E., Makombe S., Harries A.D., Chimzizi R., Salaniponi F.M., Schouten E.J., Et al., Scaling up antiretroviral therapy in Africa: Learning from tuberculosis control programmes - the case of Malawi, Int J Tuberc Lung Dis, 9, pp. 1062-1071, (2005)
[10]  
Libamba E., Makombe S., Mhango E., de Ascurra Teck O., Limbambala E., Schouten E.J., Et al., Supervision, monitoring and evaluation of nationwide scale-up of antiretroviral therapy in Malawi, Bull World Health Organ, 84, pp. 320-326, (2006)